United States Biotechnology & Medical Research

ADC Therapeutics SA (ADCT)

Track

Track

ADC Therapeutics SA experienced significant insider trading activity, primarily involving Redmile Group, LLC. The most recent transactions occurred in April 2026, consisting of multiple sell orders. Prior to this period, the entity engaged in both buying and selling of shares. No activity has been recorded within the last three months.
Ticker: ADCT Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ADC Therapeutics SA. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
108.83
Quantity 94,003 +38.2%
Value US$4,261,715
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
394.53
Quantity 12,227 -9.9%
Value US$2,897,369
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
271.76
Quantity 83,461 -8.1%
Value US$353,626
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
3.80
Quantity 169,265 -1.1%
Value US$643,038
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
3.75
Quantity 188,407 -1.4%
Value US$706,903
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
3.75
Quantity 196,229 -1.3%
Value US$736,251
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
3.81
Quantity 50,000 +0.4%
Value US$190,500
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
2.28
Quantity 50,000 +0.4%
Value US$114,000
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
3.81
Quantity 50,000 +0.3%
Value US$190,500
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
2.28
Quantity 50,000 +0.3%
Value US$114,000
3.2
Redmile Group, LLC Large shareholder
Transaction date
Sale
Price
2.07
Quantity 25,352 -0.2%
Value US$52,479
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
2.81
Quantity 400,000 +3.2%
Value US$1,124,000
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
2.81
Quantity 400,000 +2.6%
Value US$1,124,000
0.8
Ron Squarer Director Non-Executive Director
Transaction date
Proposed sale
Price
2.89
Quantity 6,995
Value US$20,216
0.8
Robert Azelby Director Non-Executive Director
Transaction date
Proposed sale
Price
2.89
Quantity 6,995
Value US$20,216
0.8
Victor Sandor Director Non-Executive Director
Transaction date
Proposed sale
Price
2.89
Quantity 6,995
Value US$20,216
0.8
Jean Bizzari Director Non-Executive Director
Transaction date
Proposed sale
Price
2.89
Quantity 6,995
Value US$20,216
0.8
Squarer Ron Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 6,995 -8.0%
Value US$20,216
0.8
BIZZARI JEAN-PIERRE Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 6,995 -8.1%
Value US$20,216
0.8
Pfisterer Thomas Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 1,437 -0.7%
Value US$4,153
0.8
Sandor Victor Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 6,995 -8.0%
Value US$20,216
0.8
Hug Peter Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 1,193 -0.6%
Value US$3,448
1.8
Monges Viviane Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 1,437 -1.3%
Value US$4,153
0.8
Azelby Robert Non-Executive Director
Transaction date
Sale
Price
2.89
Quantity 6,995 -11.7%
Value US$20,216
3.3
MALLIK AMEET Chief Executive Officer Executive Director
Transaction date
Sale
Price
4.48
Quantity 29,731 -2.5%
Value US$133,195
3.3
Ameet Mallik Officer and Director Executive Director
Transaction date
Proposed sale
Price
4.51
Quantity 29,731
Value US$134,195
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-02 S Sale
3.2
Redmile Group, LLC
Large shareholder
94,003 +38.2%
108.83
US$4,261,715 		94,003 +38.2% 108.83 US$4,261,715
2026-04-02 2026-04-02 S Sale
3.2
Redmile Group, LLC
Large shareholder
12,227 -9.9%
394.53
US$2,897,369 		12,227 -9.9% 394.53 US$2,897,369
2026-04-02 2026-04-01 S Sale
3.2
Redmile Group, LLC
Large shareholder
83,461 -8.1%
271.76
US$353,626 		83,461 -8.1% 271.76 US$353,626
2026-04-02 2026-04-01 S Sale
3.2
Redmile Group, LLC
Large shareholder
169,265 -1.1%
3.80
US$643,038 		169,265 -1.1% 3.80 US$643,038
2026-04-02 2026-03-31 S Sale
3.2
Redmile Group, LLC
Large shareholder
188,407 -1.4%
3.75
US$706,903 		188,407 -1.4% 3.75 US$706,903
2026-04-02 2026-03-31 S Sale
3.2
Redmile Group, LLC
Large shareholder
196,229 -1.3%
3.75
US$736,251 		196,229 -1.3% 3.75 US$736,251
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.4%
3.81
US$190,500 		50,000 +0.4% 3.81 US$190,500
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.4%
2.28
US$114,000 		50,000 +0.4% 2.28 US$114,000
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.3%
3.81
US$190,500 		50,000 +0.3% 3.81 US$190,500
2024-12-13 2024-12-11 B Purchase
3.2
Redmile Group, LLC
Large shareholder
50,000 +0.3%
2.28
US$114,000 		50,000 +0.3% 2.28 US$114,000
2024-12-06 2024-12-04 S Sale
3.2
Redmile Group, LLC
Large shareholder
25,352 -0.2%
2.07
US$52,479 		25,352 -0.2% 2.07 US$52,479
2024-07-03 2024-07-01 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +3.2%
2.81
US$1,124,000 		400,000 +3.2% 2.81 US$1,124,000
2024-07-03 2024-07-01 B Purchase
3.2
Redmile Group, LLC
Large shareholder
400,000 +2.6%
2.81
US$1,124,000 		400,000 +2.6% 2.81 US$1,124,000
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Ron Squarer

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Robert Azelby

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Victor Sandor

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 PrS Proposed sale
0.8
Jean Bizzari

Director

Non-Executive Director
6,995
2.89
US$20,216 		6,995 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Squarer Ron
Non-Executive Director
6,995 -8.0%
2.89
US$20,216 		6,995 -8.0% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
BIZZARI JEAN-PIERRE
Non-Executive Director
6,995 -8.1%
2.89
US$20,216 		6,995 -8.1% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Pfisterer Thomas
Non-Executive Director
1,437 -0.7%
2.89
US$4,153 		1,437 -0.7% 2.89 US$4,153
2024-06-18 2024-06-17 S Sale
0.8
Sandor Victor
Non-Executive Director
6,995 -8.0%
2.89
US$20,216 		6,995 -8.0% 2.89 US$20,216
2024-06-18 2024-06-17 S Sale
0.8
Hug Peter
Non-Executive Director
1,193 -0.6%
2.89
US$3,448 		1,193 -0.6% 2.89 US$3,448
2024-06-18 2024-06-17 S Sale
1.8
Monges Viviane
Non-Executive Director
1,437 -1.3%
2.89
US$4,153 		1,437 -1.3% 2.89 US$4,153
2024-06-18 2024-06-17 S Sale
0.8
Azelby Robert
Non-Executive Director
6,995 -11.7%
2.89
US$20,216 		6,995 -11.7% 2.89 US$20,216
2024-05-09 2024-05-07 S Sale
3.3
MALLIK AMEET

Chief Executive Officer

Executive Director
29,731 -2.5%
4.48
US$133,195 		29,731 -2.5% 4.48 US$133,195
2024-05-07 2024-05-07 PrS Proposed sale
3.3
Ameet Mallik

Officer and Director

Executive Director
29,731
4.51
US$134,195 		29,731 4.51 US$134,195
Explore more

More insider trading research around ADC Therapeutics SA

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America